Gilead Analysis

Part
01
of seven
Part
01

Gilead's Postioning and Popularity

Gilead Sciences dominates the overall HIV market, with its worth in the segment at around $28 billion, which translates to a market share of 53%, compared with GSK with 22% share.

GILEAD SCIENCES' MARKET POSITIONING AND POPULARITY

  • As published in the Financial Times in 2019, Gilead Sciences dominates the overall HIV market, having a market worth of around $28bn, which equates to a market share of 53%, compared with GSK's 22% share.
  • In terms of the popularity of individual drugs in 2019, Gilead's HIV Drug, Biktarvy, is on its way to becoming the biggest HIV drug in history with sales for the drug witnessing a 503% growth year over year and 41% sequentially in the second quarter of 2019, amounting to $1.16 billion.
  • Ranexa is a prescription medicine used to treat chronic angina, meaning pain or discomfort in the chest, jaw, shoulder, back, or arm.
  • The sales of Gilead in the Ranexa segment advanced by 15.62 % in the second quarter of 2019 as Gilead Sciences outperformed its competitors in this segment and increased its market share, to about 8.73 %.
  • Another HIV drug of the company, Genvoya, had a 34.9 % share in the HIV backbone market of Korea, ranking first, and followed by GSK’s Triumeq with a 24.1 % share.
  • Sovaldi is a drug used for the treatment of adult patients with chronic hepatitis C virus.
  • Historically, Gilead sciences accounts for 90% of the HCV anti-viral market.
  • Specifically, in the second quarter of 2019, Gilead Sciences' market share in the Sovaldi space was 54.73% compared to the overall market share of its competitors at 45.27%.
  • The FutureBrand Index is a global brand perception study done by PwC. Gilead Sciences' FutureBrand ranking went up to the third position in 2018, from the tenth position in 2016.
Part
02
of seven
Part
02

Gilead Sciences Revenue by Category - HIV/AIDS

The total revenue under the HIV/AIDS medicines category collected by Gilead Sciences in 2018 in the global market was $14,627 million and the total revenue for the same year in the US market was $11,654 million.

Gilead Sciences Medicines in the Disease Category — HIV/AIDS

  • Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
  • Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg)
  • Complera® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg)
  • Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg)
  • Emtriva® (emtricitabine 200 mg)
  • Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg)
  • Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg)
  • Stribild® (elvitegravir 150 mg/cobicistat 150 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
  • Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
  • Tybost® (cobicistat 150 mg)
  • Viread® (tenofovir disoproxil fumarate 300 mg)

Revenue 2019 2Q of HIV/AIDS Medicines: Gilead Sciences

  • Atripla®: $152 million in the global market and $122 million in the US market
  • Biktarvy®: $1116 million in the global market and $1023 million in the US market
  • Complera®: $123 million in the global market and $42 million in the US market
  • Descovy®: $358 million in the global market and $246 million in the US market
  • Genvoya®: $980 million in the global market and $743 million in the US market
  • Odefsey®: $387 million in the global market and $266 million in the US market
  • Stribild®: $108 million in the global market and $78 million in the US market
  • Truvada®: $718 million in the global market and $657 million in the US market
  • Viread®: $75 million in the global market and $9 million in the US market
  • Other HIV drugs: $15 million in the global market and $9 million in the US market

Revenue from HIV/AIDS Medicines 2018: Gilead Sciences

  • Atripla®: $1206 million in the global market and $967 million in the US market
  • Biktarvy®: $1184 million in the global market and $1144 million in the US market
  • Complera®: $653 million in the global market and $276 million in the US market
  • Descovy®: $1581 million in the global market and $1217 million in the US market
  • Genvoya®: $4624 million in the global market and $3631 million in the US market
  • Odefsey®: $1598 million in the global market and $1242 million in the US market
  • Stribild®: $644 million in the global market and $505 million in the US market
  • Truvada®: $2997 million in the global market and $2605 million in the US market
  • Viread®: $307 million in the global market and $50 million in the US market
  • Other HIV drugs: $40 million in the global market and $61 million in the US market

Revenue from the HIV/AIDS Medicines Category: Gilead Sciences

  • Total revenue from HIV/AIDS medicines in 2018 in global market: $14,627 million
  • Total revenue from HIV/AIDS medicines in 2018 in the US market: $11,654 million
  • Total revenue from HIV/AIDS medicines in 2019 2Q in global market: $4.0 billion
  • Total revenue from HIV/AIDS medicines in 2018 2Q in global market: $3.7 billion
  • Total revenue from HIV/AIDS medicines in 2019 2Q in the US market: $3.231 billion
  • Total revenue from HIV/AIDS medicines in 2018 2Q in the US market: $2.861 billion

Analysis

  • 75% of Gilead Sciences' revenue comes from medicines used for treating HIV and AIDS.
  • Even as the total revenue of Gilead Sciences dipped in 2019, the revenue from HIV/AIDS medicine increased.
  • The increase in revenue in 2018 as compared to 2017 is due to the launch of the new HIV/AIDS medicine, Biktarvy®.
  • Genvoya and Truvada are the highest revenue-bringing HIV/AIDS medicines of Gilead Sciences.
  • The United States is the most significant market for the HIV/AIDS medications produced by Gilead Sciences

RESEARCH METHODOLOGY

We included the total revenue of Gilead Sciences from the HIV/AIDS category of medications for the year 2018 and second quarter of 2019. The second quarter of 2019 revenue data was included to give an idea about the rising revenue from the HIV/AIDS medicines category this year. Also, the 2018 figures reveal that Genvoya and Truvada are the highest revenue-bringing HIV/AIDS medicines of Gilead Sciences. Based on an analysis of several data points, it can be assumed that revenue-wise, the US is the most significant market for the HIV/AIDS medications produced by Gilead Sciences. This assumption was made because the US revenue figures are very close to the global revenue figures of the HIV/AIDS medicine category of Gilead Sciences.
Part
03
of seven
Part
03

Gilead Sciences Revenue by Category - Liver Diseases

Gilead Sciences offers the following products for liver diseases Epclusa, Harvoni, Hepsera, Sovaldi, Vemlidy, Viread, and Vosevi.

OVERVIEW

  • Gilead Sciences creates efficient medication with fewer side effects, convenient treatments, better methods of administration, and improved resistance.
  • To make sure they deliver the best medical options, Gilead partners with universities, research institutions for the medical field, and global leaders in the pharmaceutical industry.
  • The company is making clinical and scientific advancements to elevate the standard of medicine for chronic diseases.
  • To treat liver diseases, Gilead Sciences offers the following portfolio of medicines: Epclusa, Harvoni, Hepsera, Sovaldi, Vemlidy, Viread, and Vosevi.

REVENUE BY LIVER DISEASE PRODUCT IN 2018

  • In 2018, Epclusa generated a revenue of $934 million in the US.
  • The same year, Harvoni generated $802 million in revenue from sales in the US.
  • Vemlidy sold $245 million in the US in 2018.
  • In 2018, Viread generated a sales revenue of $50 million in the US.
  • Vosevi's revenue from the US was $304 million in 2018.
  • Other products, like Hepsera and Sovaldi, generated a revenue of $137 million in the US in 2018.

REVENUE BY LIVER DISEASE PRODUCT IN 2017

  • Epclusa's revenue from the US was $2.404 billion in 2017.
  • In 2017, Harvoni generated $3.053 billion in revenue in the US.
  • $111 million was the revenue generated from sales of Vemlidy in the US in 2017.
  • Viread sold $514 million in the US in 2017.
  • The same year, Vosevi generated $267 million in revenue in the US.
  • Others products, including Hepsera and Sovaldi, generated a revenue of $283 million in the US in 2017.

RESEARCH STRATEGY

We began our research by doing a scan of the company’s website to identify the medications offered by Gilead Sciences in the liver diseases' category.

After this, we searched through the company's annual reports and financial statements to determine the revenue generated by these products in 2018 and 2017. We found that the company's official earnings release of 2018 has revenue information for both years in the US. While there was information available for their global market, we limited our geographic focus to the US.
However, the company published the revenue for Hepsera and Sovaldi combined with Cayston, a drug for inflammation/respiratory treatment and not for liver diseases. Since the breakdown of the "Others" category was not available through this source, we could not determine the exact revenue for these two medications.

As our next step, we searched through media publications and databases specialized in the pharmaceutical industry, like Market Realist and Reuters. Our objective was finding articles or publications with information about Hepsera, Sovaldi, or Cayston's revenue. We intended to combine the information with the revenue in the "Others" category of the report, to get the exact profit from these products. However, most sources gave information on the company's revenue and not the one specific to Hepsera, Sovaldi, and Cayston.
Our next strategy was to search in news articles, analyst reports, and press releases such as Business Wire and Biospace, for interviews and official statements from the company's leaders about the financial performance of Hepsera, Sovaldi, and Cayston. But once again, this search only brought confirmation of the company's overall revenue and not the one from Hepsera, Sovaldi, and Cayston.
We concluded that the exact revenue for Hepsera, Sovaldi, and Cayston is not publicly available. A possible reason could be that since the revenues of these products are comparatively lower than others, the company has seen no need to present them separately to their investors. It is also possible that since the company has not published the financial information of Hepsera, Sovaldi, and Cayston, none of the industry databases have been able to provide them.

Finally, we were able to provide the specific medication that Gilead Sciences offers for liver diseases and the 2017 and 2018 revenues for most products in the US. Additionally, since we could not determine the exact revenue for Hepsera and Sovaldi, we provided their combined revenue with Cayston, as a reference of their value.


Part
04
of seven
Part
04

Gilead Sciences Revenue by Category - Hematology/Oncology/Cell Therapy

In this brief, we have provided details on the revenue breakdown for the Haematology/Oncology/Cell therapy category of Gilead Sciences. In this category, the company manufactures two products which are Yescarta and Zydelig.

REVENUE BREAKDOWN BY MEDICATION

1. YESCARTA

  • At the end of the 2018 fiscal year, Yescarta generated a total of $264 million in sales.
  • Approved in October 2017, Yescarta is a cell therapy known as "CAR-T". It is used in the fight against some blood cancers.
  • The medication which is highly-priced at a minimum of $373,000, contributes to prolonging up to 40% of patients life by an additional 2 years or more.
  • The drug was originally manufactured by Kite, which was acquired by Gilead Sciences in 2017.

2. ZYDELIG

  • At the end of its 2017 fiscal year, Zydelig generated $149 million in total sales.
  • Zydelig is known as the "first-in-class P13K delta inhibitor" approved for treating some blood cancers.

RESEARCH STRATEGY

Since Gilead Sciences is a publicly listed company, we commenced our research on the company's website to identify its most recent annual report. In the report, we were able to retrieve information on the Haematology/Oncology/Cell therapy drug Zydelig, including the total amount generated from the sale of the drug in sales. For Yescarta, the company report failed to provide an exact amount generated by the drug. In this case, we expanded our research and were able to discover a press release by the company stating the amount generated from the sales of the drug in 2018. We also made use of third-party sources such as Reuters to provide a little more information on the drug.
Part
05
of seven
Part
05

Gilead Sciences Revenue by Category - Cardiovascular

Gilead Science's cardiovascular drugs are Letairis, Lexiscan and Ranexa. However, Lexiscan is sold and marketed by Astellas Pharma in the United States. U.S. sales of Letairis were $943 million while those of Ranexa were $758 million in 2018. Below are detailed annual sales of these products in the U.S.

LETAIRIS

RANEXA

LEXISCAN

RESEARCH STRATEGY:

In order to establish the revenues generated by Gilead Sciences on their cardiovascular drugs, your research team employed a number of research strategies. The team commenced by reviewing the official website of Gilead Science to gather data on the company's cardiovascular drug offering. Having identified the specific drugs offered by the company, we browsed the company's press release, financial reports and other relevant reports for data relating to these products' revenues. Using this approach we were able to identify the annual revenues for Letairis and Ranexa. However, revenues for Lexiscan were not available as this product was marketed by Astellas Pharma in the U.S.

Having established that Lexiscan was commercialized by Astellas Pharma, we expanded our search to include Astellas Pharma's press release, annual reports and other resources by the company. We were able to locate the product's 2016 annual sales revenue for the US. Unfortunately, the company did not provide its sales revenue for the product, for either year 2018 nor 2017. Instead, the company provided revenue data for Lexiscan lumped together with Adenoscan for years 2015 and 2017.

Since we were unsuccessful in our previous attempts to locate Lexiscan recent U.S. annual revenue, we opted to analyze business publications (like Forbes and Bloomberg), pharmaceutical publication (for instance, Pharmacy Times) and industry associations (like AHA). This strategy provided us with data on the amount spent by U.S. hospitals (in 2017) in procuring Lexiscan. We concluded that recent total sales revenues of Lexiscan in the U.S. were publicly unavailable.
Part
06
of seven
Part
06

Gilead Sciences Revenue by Category - Inflammation/Respiratory

Given the unavailability of the required information in the public domain, our research team estimated a revenue range of Gilead's respiratory drug business. Gilead's inflammation/respiratory drugs generated between $24 million and $100 million in 2018.

FINDINGS

  • Gilead's respiratory drug sales in the US generated between $24 million and $100 million in 2018.
  • Gilead sells only one respiratory drug Cayston. Tamiflu, its other respiratory drug, is licensed to Roche. Roche pays Gilead a 14-22% royalty.
  • Roche's US Tamiflu sales in 2018 were CHF 168 million ($171 million).
  • Gilead sold $137 million worth of Cayston, Hepsera, and Sovaldi in the US in 2018.
  • Glaxo SmithKline, AstraZeneca, and Roche were the top respiratory drug companies globally in 2016 (please refer to page two of the cited document). Gilead does not feature among the top ten respiratory drug companies in the world.
  • Seven of the top 20 respiratory drug brands in the US are owned by Glaxo SmithKline.

RESEARCH STRATEGY

In order to fulfill this request, we first searched Gilead's 2018 annual report. Gilead generated revenue from two inflammation/ respiratory drugs: Tamiflu and Cayston. While Cayston is marketed by Gilead, Tamiflu is licensed to Roche, and Gilead makes royalty of 14-22% on its sales (depending on sales value). Gilead's annual report does not provide the revenue generated from sales of Cayston, neither does it provide the royalty revenue from Tamiflu. The combined sales of Cayston, Hepsera, and Sovaldi in the US in 2018 was $137 million. The total royalty revenue (global) that Gilead made in 2018 was $114 million.

Further, we searched Roche's annual report for the royalty paid to Gilead for Tamiflu. While we did not find the royalty data, we found that Roche sold CHF 378 million ($385 million) worth of Tamiflu globally, and CHF 168 million in the US. Next, we searched for the revenue generated by the top respiratory drug companies. We found a report by PM Live, which lists the top 10 respiratory drug companies in the world. Gilead is not among the top drug 10 respiratory companies, although Roche is. In 2016, the top respiratory drug company in the world was Glaxo SmithKline ($9,677 million) and the 10th largest was Sumitomo Dainippon Pharma ($385 million).

As Gilead markets only one drug, Cayston, there was a possibility that it is among the top respiratory drugs in the United States, even though Gilead is not among the top respiratory drug companies in the world. Based on this possibility, we then searched for the top respiratory drugs in the United States. However, Cayston is not listed among the top 20 respiratory drugs in the United States. Seven of the top 20 respiratory drugs in the US are sold by Glaxo SmithKline. Following the above strategies, we extensively looked for the information in industry portals such as Fierce Pharma, Drugs.com, Pharma Cupboard, and Pharma IQ; industry reports published by McKinsey, Ernst & Young, and PWC. A report on the drug Cayston by Datamonitor Healthcare we found was paywalled. However, we did not find any pertinent data precompiled.

The sales of Cayston, Hepsera, and Sovaldi combined is only $320 million globally and $137 million in the US. The individual revenue of these drugs has not been published because they are insignificant. Among the drugs for which Gilead has published individual sales data, Zydelig has the lowest sales. In 2018, Zydelig drug sales amounted to $133 million globally and $61 million in the US. The US sales of Zydelig make up 45.9% (137/320) of its global sales, and that of Cayston, Hepsera, and Sovaldi combined make up 42.8% (61/133). Therefore, it is reasonable to assume that Cayston's sales will most likely be under $61 million (Zydelig's US sales) in the United States.

As Roche sold CHF 378 million ($385 million) worth of Tamiflu globally, and CHF 168 million in the US, Roche's Tamiflu revenue in dollar terms is $171 million (168M*385M/378M). Given that Roche pays Gilead a royalty of 14-22%, the revenue from Tamiflu royalty that Gilead earned would be in the range of $24 million ($171M*14%) and $38 million ($171m*22%). Therefore, we can say that Gilead does not make more than $99 million ($61M+$38M) in respiratory drug revenue. Please note that the source that provides the royalty revenue structure agreed between Gilead and Roche is an old source. However, as we did not find any recent sources containing this information, and because typically royalty revenue share in the pharmaceutical industry is 8-18%, we can say with a fair bit of certainty that Gilead's respiratory drug revenue in the US is under $100 million. Alternately, we can also say that Gilead's respiratory drugs generated between $24 million and $100 million in the US in 2018.

Part
07
of seven
Part
07

Gilead Sciences Revenue by Category - Other Medicines

The annual U.S. sales in 2018 for Letairis®, Ranexa®, and AmBisome®, that make up the "Other Medicines" sales were $943 million, $758 million, and $46 million respectively. Thus, the cumulative U.S. sales for this category in 2018 was $1.747 billion, with the global sales reached $2.121 billion.

KEY FINDINGS

Gilead Sciences, being a public company, categorizes the medicines by sales/revenue in its annual report, while it categorizes differently (disease-specific) on the website for marketing. The medicines under the category "Other Medicines" as provided by the audited 2018 report are Letairis®, Ranexa®, and AmBisome®.

US Sales

  • AmBisome sales for the U.S. region in 2018 was $46 million.
  • Letairis sales for the U.S. region in 2018 was $943 million.
  • Ranexa sales for the U.S. region in 2018 was $758 million.
  • Total sales in the U.S. region for the "Other Medicine" category in 2018 was $1.747 billion.

Global Sales

  • AmBisomeg global sales in 2018 was $420 million.
  • Letairis global sales in 2018 was $943 million (Only sold in the U.S.).
  • Ranexa global sales in 2018 was $758 million (Only sold in the U.S.).
  • Total global sales for the "Other Medicine" category in 2018 was $2.121 billion.

Additional Insights on Macugen (Pegaptanib)

  • Macugen was produced by Eyetech utilizing technology that was licensed from Gilead. This medicine was last promoted by Valeant Pharmaceuticals in the United States, a company that acquired Eyetech in the year 2012. Valeant enjoys exclusive licenses to both manufacture and market Macugen in the country.
  • Valeant Pharmaceuticals renamed itself Bausch Health Companies in an attempt to strengthen its image after a couple of years controversies surrounding pricing practices.
  • Macugen, released in market sometime in 2004 post-approval, came to a patent expiration in January 2017, after which generic alternatives with the same composition of Pegaptanib (Macugen's generic name) found their way onto the market.
  • In 2005, Macugen achieved total sales of around $185 million in the United States in its first complete year of sales. However, protein-based anti-VEGF therapeutics like Eylea (aflibercept), Lucentis (ranibizumab), and Avastin soon displaced it due to better performance.
  • By the year 2010, sales of Macugen declined to just $12 million annually due to aggressive competition from Lucentis (ranibizumab; Novartis).
  • The primary reason for the short-lived success of Macugen was the difference between it and Lucentis. While Macugen could suspend the development of wet AMD, Lucentis could repair vision impacted by AMD. Therefore, Macugen sales significantly diminished due to substandard efficacy compared to Lucentis.

Methodology:

Logic behind defining the "Other Medicines" category

Intensive research revealed that Gilead categorizes medicines differently on its website than its annual report. While the audited annual report's results are categorized based on the revenues (which is required in this research), the website classification may be based on other parameters like marketing, or by disease classification. Hence, the "Other Medicines" category has been defined, including those medicines that are listed in the latest annual report of the company, segregated by revenue. The medicines that have been included in the category are Letairis®, Ranexa® and AmBisome® for which both US sales and global sales have been provided. The individual sales of each medicine has also been provided. Information on Macugen has additionally been researched for this request and an explanation follows.

Reasoning behind Macugen information

  • We have searched for information related to Macugen, since it does not fall under any other category otherwise. However, recent sales figures do not exist due to the reasons stated below:
  • The patent for the medicine expired in January 2017 and generics by other manufacturers appeared in the market.
  • The medicine had already lost competition by the end of 2010 to other better alternatives in the market (like Lucentis, Avastin etc.) and reported a sharp decline of 93% in just five years starting from $185 million in 2005 to a mere $12 million in 2010.
  • Macugen was originally developed by Eyetech administering a technology that was licensed from Gilead. Thus, Gilead just accounted for royalties through the sale of the medicine in the United States. Eyetech was acquired by Valeant in 2012, while Valeant itself underwent a name change to Bausch Health Companies, owing to long stated controversies over pricing practices. All of this resulted in none of the companies providing any documented sales for Macugen over the years.

Research Strategies:

First, we searched for information directly from the respective websites of Gilead, Eyetech, Valeant, and Bausch. Though hard data on the sales numbers were unavailable, we deduced much information related to the product. Moreover, we made attempts to search for information on Macugen sales from press releases, corporate presentations, and various other company-related documents and links, but we could not locate sales information for the medicine.

Next, we searched through medical journals and research sites like OmicsOnline, iMedPub, BMJ, NCBI, etc., hoping to gather information focused on the research of this medicine and thus early information like the release, patent, etc. We were able to cite some useful information and included it in the research, which led us to understand the stiff competition this medicine faced right from its early days in the market.

We then scanned through statistical data from sites like Statista, IBIS World, PSI Web, Drug Abuse, etc., after observing a market trend of drugs being used to cure AMD. It is the same disease which Macugen is also known to cure. However, we found that no such recent statistics existed for the medicines of AMD that named Macugen as one of its cures. Thus, no recent market report named the medicine or its therapeutic use.

Following this, we attempted to triangulate an answer. We wanted to gather the year over year (YoY) of CAGR and find current sales statistics utilizing these values. Also, we could have obtained the number of unit sales for one year and multiply it with the unit price. Nevertheless, recent figures on the volume of units sold were unavailable, nor was there any recent data on the CAGR or YoY. We identified figures from 2005 and 2010, which suggested a steep decline of about 93% in just five years, which could be applied for effective calculation.

Afterward, we searched for the sales of Macugen through the top pharma retail chains in the United States like CVS, Walgreens, Walmart, and Rite Aid, among others. However, no comprehensive revenue figures were reported by any of these stores. Other thorough research steps finally deduced that the drug, apart from undergoing multiple handovers of companies, also faced fierce competition from better performing drugs and hence was either phased out or declined after its patent expired in early 2017.
Sources
Sources

From Part 01
Quotes
  • "Gilead currently dominates the overall HIV market, worth around $28bn, with around 53 per cent share compared with only about 22 per cent for GSK"
Quotes
  • "Biktarvy appears to be well on its way to becoming the biggest HIV drug in history. Sales for the drug skyrocketed 503% year over year and 41% sequentially in the second quarter to $1.16 billion. "
Quotes
  • "According to data from IQVIA, Genvoya had 34.9 percent share in the HIV backbone market, ranking first. "
  • "This year, Genvoya also topped the “third agent” market with a 32.3 percent share. The third agent refers to the agent next to the two backbone drugs in cocktail therapies."
  • "Including backbone and the third agent, Genvoya sold more than 7 billion won ($6.5 million) in the first quarter, and Stribild, 480 million won. The second place went to GSK’s Triumeq with 24.1 percent share, or 4.9 billion won in sales."
Quotes
  • "Ranexa segment sales advanced by 15.62 % Gilead Sciences Inc outperformed its competitors in this segment and improved market share, to approx. 8.73 %."
Quotes
  • "RANEXA is a prescription medicine used to treat angina that keeps coming back (chronic angina)."
  • "Chronic angina means pain or discomfort in the chest, jaw, shoulder, back, or arm that keeps coming back. "
Quotes
  • "SOVALDI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV)"
Quotes
  • "Historically this has resulted in Gilead Sciences Inc attaining around 80% of the HIV anti-viral market share and 90% of the HCV anti-viral market share"
Quotes
  • "The FutureBrand Index is a global brand perception study of the PwC Global Top 100 Companies by market capitalization. Now in its fourth year, our ranking re-orders the Top 100 in terms of brand perception strength, rather than just financial strength, offering the only rigorous assessment of how future proof the world’s most prominent companies are."
From Part 07
Quotes
  • "Macugen® (pegaptanib sodium injection) is an intravitreal injection of an anti-angiogenic oligonucleotide for the treatment of neovascular agerelated macular degeneration. Macugen was developed by Eyetech Inc. (Eyetech) using technology licensed from us and is now promoted in the United States by Valeant Pharmaceuticals, Inc. (Valeant), which acquired Eyetech in 2012. Valeant holds the exclusive rights to manufacture and sell Macugen in the United States."
Quotes
  • "Farewell, Valeant Pharmaceuticals. Hello, Bausch Health Companies. The embattled drugmaker is changing its name to Bausch Health Companies as it seeks to improve its image after a rough couple of years filled with controversies over its pricing practices."
Quotes
  • "Macugen reached peak sales of $185 M (United States) in its first full year of sales (2005). Since that time, it has been substantially displaced by protein-based anti-VEGF therapeutics: Lucentis (ranibizumab), Avastin, and Eylea (aflibercept)."
Quotes
  • "Sales of Macugen were satisfactory from 2004 through 2011. However, by 2010, sales had declined to only $12 million/year in the face of stiff competition from Lucentis (ranibizumab; Novartis)."
  • "Nevertheless, as of 2017, Macugen still retains a relatively small, though somewhat precarious, market share for the treatment of AMD"
Quotes
  • "The major difference between Macugen and Lucentis was that Macugen could halt the progression of wet AMD, but Lucentis could actually restore vision that had been lost to the disease. The result was that Macugen’s success was very short lived."
Quotes
  • "After Lucentis was approved in 2006 for wet AMD, Macugen sales declined precipitously as its efficacy is inferior to Lucentis."